Dr Reddy's recalls 80,000+ bottles of Atorvastatin from US
The product is being recalled through three separate letters to the drug regulator. Dr Reddy's officials were not immediately available for comment. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 8, 2018 Category: Pharmaceuticals Source Type: news
Class 2 Medicines Recall: Lipitor (Atorvastatin) 80mg film-coated tablets / Atorvastatin 80mg film-coated tablets, Almus livery
The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a class 2 medicines recall for specified batches of Lipitor (Atorvastatin) 80mg film-coated tablets / Atorvastatin 80mg film-c (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 27, 2017 Category: Drugs & Pharmacology Source Type: news
The effect of local and systemic statin use as an adjunct to non-surgical and surgical periodontal therapy —A systematic review and meta-analysis
ConclusionsSignificant additional clinical and radiographic improvements are obtained after local, but not systemic, statin use as an adjunct to SRP in deep pockets associated with intrabony defects and seemingly with furcation defects; intrasurgical statin application seems similarly beneficial. Confirmation of these results, and especially of the effect size, from other research groups is warranted. (Source: Dental Technology Blog)
Source: Dental Technology Blog - October 20, 2017 Category: Dentistry Source Type: news
Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Statins are a class of drugs widely used for lowering high cholesterol levels through their action on 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme in the synthesis of cholesterol. We studied the effects of two major statins,simvastatin and atorvastatin, on five Candida species andAspergillus fumigatus. The statins strongly inhibited the growth of all species, except Candida krusei. Supplementation of Candida albicans and A. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 11, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news
Atorvastatin Treatment and Risk of Diabetic Foot Infection Atorvastatin Treatment and Risk of Diabetic Foot Infection
Previous atorvastatin use may help protect against the development of diabetic foot infection among adult patients with diabetes, a new study reports.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 30, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Does Lipitor Help Rheumatoid Arthritis?
Title: Does Lipitor Help Rheumatoid Arthritis?Category: Doctor's& Expert's views on SymptomsCreated: 8/15/2017 12:00:00 AMLast Editorial Review: 8/15/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - August 15, 2017 Category: Rheumatology Source Type: news
Give chronic kidney disease patients a statin, doctors urged
20 mg of atorvastatin will help curb their risk of cardiovascular disease, says NICE Related items fromOnMedica Taking statins linked to improved heart structure and function Statins' side effects have been overstated, study suggests Salt intake linked to CVD risk in kidney patients Diet for lowering blood pressure also reduces risk of kidney disease Kidney cancer drug approved for NHS use (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 27, 2017 Category: UK Health Source Type: news
Is Lipitor Safe if I Have Fatty Liver?
Title: Is Lipitor Safe if I Have Fatty Liver?Category: Doctor's& Expert's views on SymptomsCreated: 6/29/2017 12:00:00 AMLast Editorial Review: 6/29/2017 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - June 29, 2017 Category: Cardiology Source Type: news
Statins side effects 'have been overstated', says study
Conclusion
This is a complex study that provides a plausible explanation for the difference in reports of adverse effects of statins in RCTs and observational studies, some of which have suggested as many as 1 in 5 people get side effects from statins.
However, we need to be aware of some limitations and unanswered questions:
When people knew they were taking statins, they were more likely to report muscle pain than those not taking statins. But they were less likely to report muscle pain than in the first phase of the study, when they didn't know whether they were taking statins or placebo. We don't know why this is. ...
Source: NHS News Feed - May 3, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news
Statins side effects 'have been overstated,' says study
Conclusion
This is a complex study that provides a plausible explanation for the difference in reports of adverse effects of statins in RCTs and observational studies, some of which have suggested as many as 1 in 5 people get side effects from statins.
However, we need to be aware of some limitations and unanswered questions:
When people knew they were taking statins, they were more likely to report muscle pain than those not taking statins. But they were less likely to report muscle pain than in the first phase of the study, when they didn't know whether they were taking statins or placebo. We don't know why this is. ...
Source: NHS News Feed - May 3, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news
' Suggestion' of Brain Changes on Statins by fMRI in STOMP'Suggestion' of Brain Changes on Statins by fMRI in STOMP
Despite few differences at cognitive testing for patients on atorvastatin vs placebo in the STOMP substudy,"small but significant" neuronal changes were seen on statins, their meaning unclear.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 23, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
New drug shows promise in preventing heart attacks
Conclusion
This is a high-quality, well-conducted randomised controlled trial conducted in a very large number of people across multiple countries.
To date, it's remained uncertain whether evolocumab reduces the risk of cardiovascular events.
This study provides good evidence that the drug reduces the risk of major cardiovascular events in people with high LDL cholesterol levels, and with a high risk of having a cardiovascular event, who are already taking statins.
The follow-up is limited to around two years, during which roughly 1 in 10 people experienced a cardiovascular event.
The reduction in risk was shown to inc...
Source: NHS News Feed - March 20, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news
